Geode Capital Management
QNCX icon

Geode Capital Management’s Quince Therapeutics QNCX Stock Holding History

Geode Capital Management’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-2,619
Closed -$1.76M – 4580
2025
Q4 		$1.76M Buy
2,619
+433
+20% +$218K ﹤0.01% 3209
2025
Q3 		$713K Buy
2,186
+201
+10% +$66.9K ﹤0.01% 3499
2025
Q2 		$655K Buy
1,985
+6
+0.3% +$1.37K ﹤0.01% 3469
2025
Q1 		$526K Buy
1,979
+99
+5% +$30.2K ﹤0.01% 3522
2024
Q4 		$703K Buy
1,880
+184
+11% +$55.3K ﹤0.01% 3491
2024
Q3 		$263K Buy
1,696
+331
+24% +$47.4K ﹤0.01% 3815
2024
Q2 		$205K Buy
1,365
+31
+2% +$5.6K ﹤0.01% 3900
2024
Q1 		$283K Buy
1,334
+25
+2% +$6.21K ﹤0.01% 3817
2023
Q4 		$275K Buy
1,309
+211
+19% +$42.3K ﹤0.01% 3836
2023
Q3 		$246K Buy
1,098
+162
+17% +$42.3K ﹤0.01% 3900
2023
Q2 		$282K Buy
936
+251
+37% +$78.1K ﹤0.01% 3893
2023
Q1 		$214K Hold
685
– – ﹤0.01% 4015
2022
Q4 		$87K Sell
685
-46
-6% -$7.69K ﹤0.01% 4444
2022
Q3 		$194K Hold
731
– – ﹤0.01% 4229
2022
Q2 		$324K Sell
731
-685
-48% -$484K ﹤0.01% 3992
2022
Q1 		$1.75M Sell
1,416
-132
-9% -$180K ﹤0.01% 3320
2021
Q4 		$3.91M Sell
1,548
-101
-6% -$616K ﹤0.01% 3027
2021
Q3 		$30.2M Buy
1,649
+140
+9% +$2.23M ﹤0.01% 1691
2021
Q2 		$16M Buy
1,509
+212
+16% +$1.78M ﹤0.01% 2122
2021
Q1 		$9.34M Buy
1,297
+117
+10% +$842K ﹤0.01% 2409
2020
Q4 		$6.55M Sell
1,180
-26
-2% -$230K ﹤0.01% 2442
2020
Q3 		$12.1M Buy
1,206
+355
+42% +$3.23M ﹤0.01% 1843
2020
Q2 		$7.88M Buy
851
+179
+27% +$1.64M ﹤0.01% 2075
2020
Q1 		$6.13M Buy
672
+138
+26% +$1.36M ﹤0.01% 2021
2019
Q4 		$6M Buy
534
+251
+89% +$1.51M ﹤0.01% 2337
2019
Q3 		$1.41M Buy
283
+13
+5% +$80K ﹤0.01% 3106
2019
Q2 		$2.29M Buy
+270
New +$1.61M ﹤0.01% 2858

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
SC
Shay Capital New York $1.56B AUM 46.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.7B AUM 77.3% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Fiduciary Trust
Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return

Geode Capital Management's QNCX Position: Q1 2026 in Review

Geode Capital Management sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 2,619 shares — an estimated $1.76M sold.

Geode Capital Management first reported a position in QNCX in Q2 2019 and held it in 27 quarters. The position peaked at $30.2M in Q3 2021. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Geode Capital Management reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Geode Capital Management sold 2,619 Quince Therapeutics shares in Q1 2026, an estimated $1.76M.
  • Geode Capital Management first reported a position in Quince Therapeutics in Q2 2019 and held it in 27 quarters.
  • Geode Capital Management's Quince Therapeutics position peaked at $30.2M in Q3 2021.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Geode Capital Management's 13F filing for Q1 2026, filed 15 May 2026.